MBMichael G. Bruce

Michael G. Bruce

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael G. Bruce has a total of 357 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas W. Hennessy

    The Arctic Investigations Program, National Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska

    9 shared publications
  • Lisa Bulkow

    The Arctic Investigations Program, National Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska

    8 shared publications
  • Dana Bruden

    Division of Preparedness and Emerging Infections,National Center for Emerging and Zoonotic Infectious Diseases,Arctic Investigations Program,Centers for Disease Control and Prevention,Anchorage,Alaska,USA

    7 shared publications
  • Karen Rudolph

    The Arctic Investigations Program, National Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska

    7 shared publications
  • Tammy Zulz

    Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska, USA

    6 shared publications
  • Thomas Hennessy

    Division of Preparedness and Emerging Infections,National Center for Emerging and Zoonotic Infectious Diseases,Arctic Investigations Program,Centers for Disease Control and Prevention,Anchorage,Alaska,USA

    6 shared publications

Latest Publications

  • A respiratory illness surveillance pilot project among people experiencing homelessness – Anchorage, Alaska, 2023–2024

    by Rieza H. Soelaeman, Kathleen M. Tatti, Kara Norby, Shelly Budde, Carolynn DeByle, Brenna Simons, Michael G. Bruce, Emily Mosites, Hannah L. Kirking, Melissa Rolfes, et al.

    People experiencing homelessness (PEH) are at increased risk of respiratory infections and adverse health outcomes, including complications, hospitalization, and death, compared to people not exper...

  • Open Access

    Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project

    by Yangyupei Yang, Maria Deloria Knoll, Carly Herbert, Julia C. Bennett, Daniel R. Feikin, Maria Garcia Quesada, Marissa K. Hetrich, Scott L. Zeger, Eunice W. Kagucia, Melody Xiao, et al.


  • An Investigation of Pediatric Case-patients With Invasive Haemophilus influenzae in Alaska, 2005–2011

    by Leisha Diane Nolen, Lisa Bulkow, Rosalyn Singleton, Debbie Hurlburt, Carolyn Debyle, Karen Rudolph, Laura L. Hammitt, Thomas W. Hennessy, Michael G. Bruce

    Background: Haemophilus influenzae (Hi) can cause severe disease in children. This study aimed to identify risk factors related to invasive Hi disease in Alaska children and evaluate carriage in people around them. Methods: From 2005 to 2011, we investigated episodes of invasive, typeable Hi disease in Alaska children P = 0.001), other carriers of any Hi in their household (61% vs. 15%, P < 0.001), and inadequate Hib vaccination (26% vs. 9%, P = 0.005). People who carried Hi were younger than noncarriers (mean 12.7 vs. 18.0 years, P = 0.008). The carriage was clustered within case-patient households, with carriage in 19% of household contacts, while only 6.3% of nonhousehold contacts and 5.5% of noncontacts carried the Hi serotype of interest (P < 0.001). Conclusions: Factors associated with invasive Hi disease in children included underlying health problems, household carriage and inadequate Hib vaccination. The high level of carriage in case-patient households is important to consider when evaluating treatment and prophylaxis strategies.


  • Rate and durability of the clearance of HBsAg in Alaska Native persons with long-term HBV infection: 1982–2019

    by Dana Bruden, Brian J. McMahon, Mary Snowball, Lisa Towshend-Bulson, Chriss Homan, Janet M. Johnston, Brenna C. Simons, Michael G. Bruce, Laurie Cooley, Philip R. Spradling, et al.

    Backround & Aims: A functional cure and therapeutic endpoint of chronic hepatitis B virus (HBV) infection is defined as clearance of hepatitis B surface antigen (HBsAg) from serum. Little is known about the long-term durability of HBsAg loss in the Alaskan Native population. Approach & Results: We performed a retrospective cohort study of Alaskan Native patients with chronic HBV-monoinfection from January, 1982 through December 2019. The original group in this cohort were identified during a 1982 to 1987 population-based screening for three HBV serologic markers in 53,000 Alaska Native persons. With close to 32,000 years of follow-up, we assessed the frequency and duration of HBsAg seroclearance (HBsAg negative for >6 mo). We examined factors associated with HBsAg clearance and followed persons for a median of 13.1 years afterwards to assess durability of HBsAg clearance. Among 1,079 persons with an average length of follow-up of 33 years, 260 (24%) cleared HBsAg at a constant rate of 0.82% per person/per year. Of 260 persons who cleared, 249 (96%) remained HBsAg negative while 11 persons had≥ 2 transient HBsAg positive results in subsequent follow-up. Conclusions: Of patients with chronic HBV monoinfection, 0.82% of people per year achieved a functional cure. HBsAg seroclearance was durable for treated and non-treated patients and lasted on average over 13 years without seroreversion. The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the Centers for Disease Control and Prevention Export


  • Epidemiology of invasive Haemophilus influenzae serotype a disease in the North American Arctic, 2006–2017

    by Tammy Zulz, Grace Huang, Karen Rudolph, Carolynn DeByle, Raymond Tsang, Shalini Desai, Stephanie Massey, Michael G Bruce

    Invasive Haemophilus influenzae type a (iHia) disease was detected in Alaska and Northern Canada in 2002 and 2000, respectively. From 2006 to 2017, 164 iHia cases (Alaska=53, Northern Canada=111) were reported. Rates of iHia disease per 100,000 persons were higher in Northern Canada compared to Alaska and were significantly higher in Indigenous (Alaska 2.8, Northern Canada 9.5) compared to non-Indigenous populations (Alaska 0.1, Northern Canada=0.4). Disease rates were highest in Indigenous children <2 years of age (Alaska 56.2, Northern Canada=144.1) and significantly higher than in non-Indigenous children <2 (Alaska 0.1, Northern Canada 0.4). The most common clinical presentation in children <5 years was meningitis of age and pneumonia in persons ≥5 years old. Most patients were hospitalised (Alaska=87%, Northern Canada=89%) and fatality was similar (Alaska=11%, Northern Canada=10%). MLST testing showed sequence types ST23 and ST576 in Northern Canada and ST576, ST23 and ST56 in Alaska. Alaska and Northern Canada have high rates of iHia disease. A vaccine is needed in these regions to protect young children.


  • Open Access

    Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose

    by Michael G. Bruce, Dana Bruden, Debby Hurlburt, Julie Morris, Sara Bressler, Gail Thompson, Danielle Lecy, Karen Rudolph, Lisa Bulkow, Thomas Hennessy, et al.

    Background and Aims: The duration of protection from hepatitis B vaccination in children and adults is not known. In 1981, we used three doses of plasma‐derived hepatitis B vaccine to immunize a cohort of 1578 Alaska Native adults and children from 15 Alaska communities who were ≥6 months old. Approach and Results: We tested persons for antibody to hepatitis B surface antigen (anti‐HBs) levels 35 years after receiving the primary series. Those with levels <10 mIU/ml received one booster dose of recombinant hepatitis B vaccine 2–4 weeks later and were then evaluated on the basis of anti‐HBs measurements 30 days postbooster. Among the 320 recruited, 112 persons had not participated in the 22‐ or 30‐year follow‐up study (group 1), and 208 persons had participated but were not given an HBV booster dose (group 2). Among the 112 persons in group 1 who responded to the original primary series, 53 (47.3%) had an anti‐HBs level ≥10 mIU/ml. Among group 1, 73.7% (28 of 38) of persons available for a booster dose responded to it with an anti‐HBs level ≥10 mIU/ml at 30 days. Initial anti‐HBs level after the primary series was correlated with higher anti‐HBs levels at 35 years. Among 8 persons who tested positive for antibody to hepatitis B core antigen, none tested positive for HBsAg or HBV DNA. Conclusions: Based on anti‐HBs level ≥10 mIU/ml at 35 years and a 73.7% booster dose response, we estimate that 86% of participants had evidence of protection 35 years later. Booster doses are not needed in the general population at this time.


  • Open Access

    Genomic Diversity of Haemophilus influenzae Serotype a in an Outbreak Community—Alaska, 2018

    by Leisha D Nolen, Carolynn DeByle, Nadav Topaz, Brenna C Simons, Amanda Tiffany, Alisa Reasonover, Louisa Castrodale, Joseph McLaughlin, Joe Klejka, Xin Wang, et al.

    Haemophilus influenzae serotype a (Hia) can cause severe invasive disease, especially in young children. In 2018, four invasive Hia cases occurred in an Alaska community. We used whole-genome sequencing (WGS) to evaluate the relationship of the bacteria from this community and other Alaska patients with invasive Hia. All carriage (15) and invasive (4) Hia isolates from the outbreak community, together with 15 non-outbreak Alaska invasive Hia surveillance isolates from 2018, were tested for antimicrobial susceptibility and characterized using WGS. Phylogenetic analysis of both invasive and carriage Hia isolates revealed two major clades that differed by an average of 300 core single nucleotide polymorphisms (SNPs). All isolates from the outbreak community were clustered in one subclade, within a larger clade containing 3 non-outbreak invasive Hia isolates. Comparative genomics did not reveal any genetic mutations that distinguished carriage from invasive isolates. Three (20%) community isolates were rifampin-resistant and had a previously unreported mutation in the rpoB gene. In the outbreak community, Hia isolates from carriers were indistinguishable from the invasive Hia isolates. Overall, invasive Hia isolates from Alaska in 2018 were genetically similar. The rifampin resistance mutation is concerning as rifampin is the first-line medication for Hia prophylaxis.


  • Open Access

    Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project

    by Maria Deloria Knoll, Julia C. Bennett, Maria Garcia Quesada, Eunice W. Kagucia, Meagan E. Peterson, Daniel R. Feikin, Adam L. Cohen, Marissa K. Hetrich, Yangyupei Yang, Jenna N. Sinkevitch, et al.

    Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.


  • Open Access

    Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project

    by Maria Garcia Quesada, Yangyupei Yang, Julia C. Bennett, Kyla Hayford, Scott L. Zeger, Daniel R. Feikin, Meagan E. Peterson, Adam L. Cohen, Samanta C. G. Almeida, Krow Ampofo, et al.

    Pneumococcal conjugate vaccine (PCV) introduction has reduced pneumococcal meningitis incidence. The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project described the serotype distribution of remaining pneumococcal meningitis in countries using PCV10/13 for least 5–7 years with primary series uptake above 70%. The distribution was estimated using a multinomial Dirichlet regression model, stratified by PCV product and age. In PCV10-using sites (N = 8; cases = 1141), PCV10 types caused 5% of cases N = 32; cases = 4503), PCV13 types caused 14% in <5 and 26% in ≥5 years; 4% and 13%, respectively, were serotype 3. Among the top serotypes are five (15BC, 8, 12F, 10A, and 22F) included in higher-valency PCVs under evaluation. Other top serotypes (24F, 23B, and 23A) are not in any known investigational product. In countries with mature vaccination programs, the proportion of pneumococcal meningitis caused by vaccine-in-use serotypes is lower (≤26% across all ages) than pre-PCV (≥70% in children). Higher-valency PCVs under evaluation target over half of remaining pneumococcal meningitis cases, but questions remain regarding generalizability to the African meningitis belt where additional data are needed.